Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: adalimumab, Abbott laboratories.

Hanns M Lorenz1

  • 1Rheumatology/Institute for Clinical Immunology, Department of Medicine III, University of Erlangen-Nuremberg, Germany. Hannes.Lorenz@med3.imed.uni-erlangen.de

Current Opinion in Molecular Therapeutics
|June 5, 2002
PubMed
Summary

Adalimumab, a TNF-alpha neutralizing antibody, is in late-stage development for inflammatory diseases like rheumatoid arthritis. Regulatory filing and market launch were anticipated for 2002-2003, with significant sales projected.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.

Clinical and experimental rheumatology·2022
Same author

Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis.

Arthritis and rheumatism·2005
Same author

Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways.

Molecular pharmacology·2004
Same author

15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy.

Journal of the American Society of Nephrology : JASN·2003

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Adalimumab (D2E7) is a human monoclonal antibody targeting Tumor Necrosis Factor alpha (TNFa).
  • It is developed for inflammatory disorders including rheumatoid arthritis (RA) and Crohn's disease, with potential applications in coronary heart disease.

Purpose of the Study:

  • To report on the development status and market projections for adalimumab.
  • To summarize the clinical trial progress and anticipated regulatory timelines.

Main Methods:

  • Review of clinical trial phases (Phase II for Crohn's disease, Phase III for RA).
  • Analysis of financial and market predictions from investment firms (Lehman Brothers, Merrill Lynch, ABN AMRO).

Main Results:

  • Phase III trials for RA were completed by January 2002.

Related Experiment Videos

  • Anticipated US approval filing in Q2 2002, with a potential 2003 market launch.
  • Projected peak US sales ranging from $600 million to $392 million annually between 2007-2008.

    • Conclusions:

    • Adalimumab demonstrated significant development progress through 2001-2002.
    • High market potential was predicted, with a 70% probability of reaching the market.